

Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-May-2019  
Document Type: USP Monographs  
DocId: GUID-F7156355-C15F-4EEB-AB3B-8FD2C8A702F1\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M87710\\_02\\_01](https://doi.org/10.31003/USPNF_M87710_02_01)  
DOI Ref: d89ge

© 2025 USPC  
Do not distribute

## Valproic Acid Oral Solution

### DEFINITION

Valproic Acid Oral Solution contains NLT 90.0% and NMT 110.0% of the labeled amount of valproic acid ( $C_8H_{16}O_2$ ). It is prepared with the aid of Sodium Hydroxide.

### IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

#### Change to read:

- **B.** ▲The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-May-2019)

### ASSAY

#### Change to read:

- **PROCEDURE**

**Buffer:** 3.5 g/L of [monobasic sodium phosphate](#) in [water](#). Adjust with [phosphoric acid](#) to a pH of 3.5.

**Mobile phase:** Acetonitrile and *Buffer* (45:55)

**Diluent:** Acetonitrile and [water](#) (45:55)

**System suitability solution:** 0.5 mg/mL of [USP Valproic Acid RS](#) and 50 µg/mL of [USP Valproic Acid Related Compound B RS](#) in *Diluent*

**Standard solution:** 0.5 mg/mL of [USP Valproic Acid RS](#) in *Diluent*

**Sample solution:** Nominally 0.5 mg/mL of valproic acid in *Diluent* from a suitable volume of Oral Solution

#### Chromatographic system

(See [Chromatography\\_\(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 215 nm. ▲For *Identification B*, use a diode array detector in the range of 200–400 nm.▲ (USP 1-May-2019)

**Column:** 4.6-mm × 15.0-cm; 5-µm packing [L7](#)

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

▲**Run time:** NLT 2 times the retention of valproic acid▲ (USP 1-May-2019)

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[**NOTE**—The relative retention times for valproic acid related compound B and valproic acid are 0.90 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 2.0 between valproic acid related compound B and valproic acid, *System suitability solution*

**Tailing factor:** NMT 1.5, *Standard solution*

**Relative standard deviation:** NMT 1.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of valproic acid ( $C_8H_{16}O_2$ ) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_s$  = concentration of [USP Valproic Acid RS](#) in the *Standard solution* (mg/mL)

$C_u$  = nominal concentration of valproic acid in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

#### SPECIFIC TESTS

- [pH \(791\)](#): 7.0–8.0

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Valproic Acid RS](#)

[USP Valproic Acid Related Compound B RS](#)

(2RS)-2-(1-Methylethyl)pentanoic acid.

$C_8H_{16}O_2$  144.21

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
VALPROIC ACID ORAL SOLUTION	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(1)

**Current DocID: GUID-F7156355-C15F-4EEB-AB3B-8FD2C8A702F1\_2\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M87710\\_02\\_01](https://doi.org/10.31003/USPNF_M87710_02_01)**

**DOI ref: [d89ge](#)**